Table of Contents Author Guidelines Submit a Manuscript
Disease Markers
Volume 23, Issue 5-6, Pages 419-431
http://dx.doi.org/10.1155/2007/257602

Markers of Angiogenesis in Ovarian Cancer

William M. Merritt1 and Anil K. Sood1,2

1Department of Gynecologic Oncology, U.T. M.D. Anderson Cancer Center, Unit 1362, P.O. Box 301439, Houston TX 77230-1439, USA
2Department of Cancer Biology, U.T. M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 173, Houston TX 77030, USA

Received 9 November 2007; Accepted 9 November 2007

Copyright © 2007 Hindawi Publishing Corporation. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Tumor development and progression are inherently dependent on the process of angiogenesis. Recently, anti-angiogenic therapy has started to show promise as an effective treatment strategy in many solid tumors including ovarian carcinoma. Unfortunately, lack of effective biomarkers presents a challenge for oncologists in treatment planning as well as monitoring response of new anti-vascular agents. Previously, quantification of angiogenesis by microvessel density analysis provided useful prognostic information, however, its utility following anti-angiogenic therapy remains to be determined. Moreover, since secreted cytokines play an active part in angiogenesis by mediating neovascularization in tumors, investigations have focused on their potential role to serve as candidate biomarkers of disease detection, prognosis, and treatment response. In this article, we review the role of key angiogenesis markers as potential biomarkers in ovarian carcinoma.